Toripalimab plus chemo for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests adding toripalimab (an immunotherapy drug) to chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if this combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have early-stage triple-negative breast cancer that has not spread beyond the breast and nearby lymph nodes.
- You must have a tumor that can be measured by imaging like ultrasound or mammogram.
- Your heart, liver, kidney, and blood cell counts must be within certain healthy ranges.
- You must not have had any prior cancer treatment for this breast cancer.
- You cannot have active autoimmune disease, hepatitis B or C, or be pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests adding the immunotherapy drugs JS004 and toripalimab to standard chemotherapy before surgery for stage II-III triple-negative breast cancer. It aims to see if combining these immunotherapies with chemo works better than chemo alone or chemo with just toripalimab.
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.